Syngene International plans to add bioconjugation suite for end-to-end Antibody-Drug conjugates development

Mumbai: Syngene International, a global contract research, development and manufacturing organization (CRDMO), is adding a GMP bioconjugation suite at its commercial biologics facility [Unit 3] in Bengaluru. With this new capability, Syngene…

Continue ReadingSyngene International plans to add bioconjugation suite for end-to-end Antibody-Drug conjugates development